Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cerivastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | PDE6D | O43924 | 1/20 | 0.58 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.49 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cerivastatin SCHEMBL16347 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL29623902 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL14879523 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL5508954 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL6241954 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL6241950 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL10024041 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL29379484 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL5508956 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL6268472 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 36624 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12640239-B2 | Functional biomarkers for statin therapy in age-related macular degeneration (AMD) | APELIOTUS TECHNOLOGIES, INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026106952-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | CDG CARE (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4745160-A1 | METHOD FOR TREATING OR PREVENTING CHOLESTEROL-RELATED DISEASES USING PCSK9 INHIBITOR | Salubris (Chengdu) Biotech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4248976-B1 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) | AMGEN INC (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260060948-A1 | METHODS FOR TREATING LIVER DISEASE | CYMABAY THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | claimed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| WO-1997028149-A1 | METHOD FOR RAISING HDL CHOLESTEROL LEVELS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | claimed |
| EP-0782451-A1 | COMBINATION OF A CHOLESTEROL ABSORPTION INHIBITOR AND A CHOLESTEROL SYNTHESIS INHIBITOR | PFIZER INC. (US) | 1997-07-09 | — | — | EP | claimed |
| WO-1997016184-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1997-05-09 | — | — | WO | claimed |
| CN-1148492-A | Treatment for arteriosclerosis and vitiligoidea | SANKYO CO (JP) | 1997-04-30 | — | — | CN | claimed |
| EP-0753298-A1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO COMPANY LIMITED (JP) | 1997-01-15 | — | — | EP | claimed |
| WO-1996009827-A2 | COMBINATION OF A CHOLESTEROL ABSORPTION INHIBITOR AND A CHOLESTEROL SYNTHESIS INHIBITOR | PFIZER INC. (US) | 1996-04-04 | — | — | WO | claimed |
| EP-0698609-A1 | Alpha-phosphorus substituted sulfinate derivatives as squalene synthetase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-02-28 | — | — | EP | claimed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| US-5356896-A | Alkaline stabiling medium | SANDOZ LTD. (CH) | 1994-10-18 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |